Balancing innovation and affordability in drug development is a complex challenge.
The research on Alzheimer's prevention is groundbreaking, potentially reducing the devastation caused by the disease.
However, significant funding is essential to continue making strides.
Producing a drug for $5 is feasible, but it doesn't cover the extensive research costs required for further advancements.
What do you think is the best way to balance these financial and innovative needs?
The Senate HELP Committee investigates why Novo Nordisk charges Americans with diabetes and obesity exorbitantly high prices for Ozempic and Wegovy.
